Michael H. Moskowitz, MD, MPH graduated from Louisiana State University Medical Center in 1977, having earned a Masters In Public Health in 1972 from Tulane University.
He completed his Psychiatric Residency and Psychosomatic Fellowship training at St. Mary's Hospital in San Francisco in 1982. That same year, Dr. Moskowitz entered Private Psychiatric and Psychosomatic Practice and served as the Medical Director of the Adult Locked Psychiatric Inpatient Teaching Unit at St. Mary's from 1982 to 1987. In 1986 he joined the Consortium of Spinal Care Physicians at St. Mary's.
He was a member of the Board of Directors of SpineCare Medical Group for four years from 1988 to 1992. The practice he helped found in 1981, Psychiatric Associates of San Francisco, changed its name in 2000 to Bay Area Pain Medical Associates, reflecting the predominant practice of Pain Medicine in this group. Dr. Moskowitz is Board Certified in both Psychiatry and Pain Medicine. Dr. Moskowitz served as a member of the Examination Council for the American Board of Pain Medicine from 2006-2010 and as the former chairman of the Educational Committee of the American Academy of Pain Medicine. He has also served on the American Academy of Pain Medicine’s Continuing Education Committee, Enduring Materials Committee and chaired the Academy’s Website redesign committee. He has pioneered the development and use of animations to teach and understand principles of pain medicine and has designed and developed the most popular website for pain animations in the world, since 1999, http://www.bayareapainmedical.com. Dr. Moskowitz was an Assistant Clinical Professor for the Department of Anesthesiology and Pain Medicine at the University of California, Davis from 2006-2016, teaching the psychiatric and neuroplastic aspects of pain medicine there, to the Pain Fellows
Dr. Moskowitz’ philosophy has been the development of a clinical practice in Pain Medicine using the Biopsychosocial approach, and the establishment of that practice as a teaching resource for physicians interested in Pain Medicine. Dr. Moskowitz has designed and delivered Continuing Medical Education courses for physicians in California to meet the requirement of AB 487 for 12 hours of CME in Pain Medicine Training for all practicing physicians in the state. Additionally, he has been selected as a frequent lecturer for the annual Conference of the American Academy of Pain Medicine. Dr. Moskowitz has published several peer reviewed journal articles and textbook chapters with a focus upon the role that brain changes play in perpetuating persistent pain states. In 2007 he pioneered development of treatment approaches based upon the most advanced scientific principles of brain neuroplasticity and pain.
In November of 2008, he began working with Marla Golden, DO, MS on Neuroplasticity and its role in the treatment of patients living with persistent pain. Together, Dr. Moskowitz and Dr. Golden have lectured on this topic around the country and have delivered several 2-12 hour seminars on this topic. Dr. Moskowitz and Dr. Golden are the co-founders of Neuroplastic Partners, LLC, a company dedicated to the promotion of Neuroplastic treatment for persistent pain. He recently co-authored the Neuroplastic Transformation Workbook designed to teach practitioners how to use neuroplastic treatment approaches and provide patients with a written guide to recover from persistent pain disorders. He also co-authored, designed and built the neuroplastix.com website with Dr. Golden.
From 2015 though the present Dr. Moskowitz has been focusing upon the use of medical cannabis in the treatment of pain and anxiety. He has written a book on the subject, Medical Cannabis: A Guide for Patients, Practitioners and Caregivers. The book organizes this treatment into methodical medical practice to reduce pain anxiety, chronic illness and long term medication use. The book emphasizes integration of this treatment into standard medical care using neuroplasticity as its central focus. It was published in November of 2017. He is developing several applications for patients to use with dispensaries to select the appropriate strains, embodiments and routes of administration for the symptoms and conditions they are trying to treat using medical cannabis. He is chairing the Medical Cannabis Research Consortium of Marin (MCRCM) to help design and carry out studies on medical cannabis “from seed to symptom.”